Serotonin Uptake in Blood Platelets of Psychiatric Patients

Archives of General Psychiatry

Volumn 38, Issue 12, 1981, Pages 1322-1326

  Meltzer, Herbert Y ^a,b   Arora, Ramesh C ^a,b   Baber, Riaz ^b   Tricou, Betty ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMIPRAMINE; NORTRIPTYLINE; RADIOISOTOPE; SEROTONIN;

BLOOD AND HEMOPOIETIC SYSTEM; CENTRAL NERVOUS SYSTEM; DEPRESSION; DRUG THERAPY; ETIOLOGY; IN VITRO STUDY; MAJOR CLINICAL STUDY; PATHOGENESIS; PSYCHOLOGICAL ASPECT; SCHIZOIDISM; SEROTONIN C 14; THERAPY; THROMBOCYTE;

ADULT; ANALYSIS OF VARIANCE; BIPOLAR DISORDER; BLOOD PLATELETS; CARBON RADIOISOTOPES; DEPRESSIVE DISORDER; FEMALE; HUMAN; MALE; NORTRIPTYLINE; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SEROTONIN; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0019801535     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archpsyc.1981.01780370024002     Document Type: Article

References (56)

1. Schildkraut JJ: The catecholamine hypothesis of affective disorder: A review of supporting evidence. Am J Psychiatry 1965;122: 509–522.
2. Lapin IP, Oxenkrug GF: Intensification of the central serotonergic processes as a possible determinant of the thymoleptic effect. Lancet 1969;1: 132–136.
3. Coppen A: The biochemistry of affective disorders. Br J Psychiatry 1967;113: 1237–1264.
4. Murphy DL, Campbell I, Costa JL: Current studies of the indoleamine hypothesis of the affective disorders, in Lipton MA, DiMascio A, Killam KF (eds): Psychopharmacology: A Generation of Progress. New York, Raven Press, 1978, pp 1235–1247.
5. Shaw DM, Camps FE, Eccleston EG: 5-Hydroxytryptamine in the hindbrain of depressive suicides. Br J Psychiatry 1967;113: 1407–1411.
6. Pare CMB, Young DPH, Price KS, et al: 5-Hydroxytryptamine, noradrenaline and dopamine in brainstem, hypothalamus and caudate nucleus of controls and of patients committing suicide by coal-gas poisoning. Lancet 1969;2: 133–135.
7. Lloyd KG, Farley IJ, Deck JHN, et al: Serotonin and 5-hydroxyindoleacetic acid in discrete areas of the brainstem of suicide victims and control patients. Adv Biochem Psychopharmacol 1974;11: 387–398.
8. Ashcroft GW, Crawford TBB, Eccleston D, et al: 5-Hydroxyindole compounds in the cerebrospinal fluid of patients with psychiatric or neurological diseases. Lancet 1966;2: 1049–1052.
9. Van Praag HM, Korf J: Retarded depression and dopamine metabolism. Psychopharmacologia 1971;19: 199–201.
10. Coppen A, Prange AJ Jr, Whybrow PC, et al: Abnormalities of indoleamines in affective disorders. Arch Gen Psychiatry 1972;26: 474–478.
11. Bourne HR, Bunney WE, Colburn RW, et al: Noradrenaline, 5-hydroxytryptamine and 5-hydroxyindoleacetic acid in the hindbrains of suicidal patients. Lancet 1968;2: 805–808.
12. Sjostrom R, Roos B-E: 5-Hydroxyindoleacetic acid and homovanillic acid in cerebrospinal fluid in manic-depressive psychosis. Eur J Clin Pharmacol 1972;4: 170–176.
13. Van Praag HM, Korf J, Schut D: Cerebral monoamines and depression: An investigation with the probenecid technique. Arch Gen Psychiatry 1973;28: 827–831.
14. Van Praag HM, Korf J, Dols LCW, et al: A pilot study of the predictive value of the probenecid test in the application of 5-hydroxytryptophan as an antidepressant. Psychopharmacologia 1972;25: 14–21.
15. Puhringer W, Wirz-Justice A, Lancranjan I: Mood elevation and pituitary stimulation after intravenous L-5-HTP in normal subjects: Evidence for a common serotonergic mechanism. Neurosci Lett 1976;2: 349–354.
16. Takahashi S, Kondo H, Kato N: Effect of L-5-hydroxytryptophan on brain monoamine metabolism and evaluation of its clinical effect in depressed patients. J Psychiatr Res 1975;12: 177–187.
17. Kline NS, Shah BK: Comparable therapeutic efficacy of tryptophan and imipramine: Average therapeutic ratings versus ‘true’ equivalence: An important difference. Curr Ther Res 1973;15: 484–487.
18. Van Hide LJ: L-5-Hydroxytryptophan in depression: The first substitution therapy in psychiatry. Neuropsychobiology 1980;6: 230–240.
19. Bowers MB Jr: Cerebrospinal fluid 5-hydroxyindoles and behaviour after L-tryptophan and pyridoxine administration to psychiatric patients. Neuropharmacology 1970;9: 599–604.
20. Murphy DL, Baker H, Goodwin FK, et al: L-Tryptophan in affective disorders: Indoleamine changes and differential clinical effects. Psychopharmacologia 1974;34: 11–20.
21. Farkas T, Dunner DL, Fieve RR: L-Tryptophan in depression. Biol Psychiatry 1976;11: 295–302.
22. Shopsin B, Friedman E, Gershon S: Parachlorophenylalanine reversal of tranylcypromine effect in depressed patients. Arch Gen Psychiatry 1976;33: 811–819.
23. Aprison MH, Takahashi R, Tachiki K: Hypersensitive serotonergic receptors involved in clinical depression: A theory, in Haber B, Aprison M (eds): Neuropharmacology and Behavior. New York, Pergamon Press, 1977, pp 23–53.
24. Ogren S-O, Fuxe K, Agnati LF, et al: Reevaluation of the indoleamine hypothesis of depression: Evidence for a reduction of functional activity of central 5-HT systems by antidepressant drugs. J Neural Transm 1979;46: 85–103.
25. Sneddon JM: Blood platelets as a model for monoamine-containing neurones. Prog Neurobiol 1973;1: 151–187.
26. Stahl SM, Meltzer HY: A kinetic and pharmacologic analysis of 5-hydroxytryptamine transport by human platelets and platelet storage granules: Comparison with central serotonergic neurons. J Pharmacol Exp Ther 1978;205: 118–132.
27. Shaw DM, MacSweeney DA, Woolcock N, et al: Uptake and release of 14C-5-hydroxytryptamine by platelets in affective illness. J Neurol Neurosurg Psychiatry 1968;34: 1–16.
28. Tuomisto J, Tukiainen E: Decreased uptake of 5-hydroxytryptamine in blood platelets from depressed patients. Nature 1976;262: 596–598.
29. Tuomisto J, Tukiainen E, Ahlfors UG: Decreased uptake of 5-hydroxytryptamine in blood platelets from patients with endogenous depression. Psychopharmacology 1979;65: 141–147.
30. Coppen A, Swade C, Wood K: Platelet 5-hydroxytryptamine accumulation in depressive illness. Clin Chim Acta 1978;87: 165–168.
31. Coppen A, Rama Rao VA, Swade C, et al: Inhibition of 5-hydroxytryptamine reuptake by amitriptyline and zimelidine and its relationship to their therapeutic action. Psychopharmacology 1979;63: 125–129.
32. Scott M, Reading HW, Loudon JB: Studies on human platelets in affective disorders. Psychopharmacology 1979;60: 131–135.
33. Born GVR, Grignani G, Martin K: Long-term effect of lithium on the uptake of 5-hydroxytryptamine by human platelets. Br J Clin Pharmacol 1980;9: 321–325.
34. Mirkin AM, Coppen A: Electrodermal activity in depression: Clinical and biochemical correlates. Br J Psychiatry 1980;137: 93–97.
35. Maas JW: Biogenic amines and depression: Biochemical and pharmacological separation of two types of depression. Arch Gen Psychiatry 1975;32: 1357–1361.
36. Wing JK, Cooper JE, Sartorius A: The Measurement and Classification of Psychiatric Symptoms. New York, Cambridge University Press, 1974.
37. Spitzer RL, Endicott J, Robins E: Research Diagnostic Criteria: Rationale and reliability. Arch Gen Psychiatry 1978;35: 773–782.
38. Endicott J, Spitzer RL: A diagnostic interview: The Schedule for Affective Disorders and Schizophrenia. Arch Gen Psychiatry 1978;35: 837–844.
39. Arora RC, Meltzer HY: A method for determining serotonin uptake in human platelets. Clin Chim Acta 1981;112: 225–233.
40. Edwards DJ, Chang S-S: Multiple forms of monoamine oxidase in rabbit platelets. Life Sci 1975;17: 1127–1134.
41. Pope HG Jr, Lipinski JF Jr: Diagnosis in schizophrenia and manicdepressive illness: A reassessment of the specificity of ‘schizophrenic’ symptoms in the light of current research. Arch Gen Psychiatry 1978;35: 811–828.
42. Tsuang MT: Schizoaffective disorder: Dead or alive? Arch Gen Psychiatry 1979;36: 633–634.
43. Hallstrom COS, Rees WL, Pare CMB, et al: Platelet uptake of 5-hydroxytryptamine and dopamine in depression. Postgrad Med J 1976;52: 40–44.
44. Ehsanullah RS: Uptake of 5-hydroxytryptamine and dopamine into platelets from depressed patients and normal subjects: Influence of clomipramine, desmethylclomipramine and maprotiline. Postgrad Med J 1980;56(suppl 1): 31–35.
45. Ross SB, Aperia B, Beck-Friis J, et al: Inhibition of 5-hydroxytryptamine uptake in human platelets by antidepressant agents in vivo. Psychopharmacology 1980;67: 1–7.
46. Oxenkrug GF: The content and uptake of 5-HT by blood platelets in depressive patients. J Neural Transm 1979;45: 285–289.
47. Modai J, Rotman A, Munetz H, et al: Serotonin uptake by blood platelets of acute schizophrenic patients. Psychopharmacology 1979;64: 193–195.
48. Todrick A, Tait AC: The inhibition of human platelet 5-hydroxytryptamine uptake by tricyclic antidepressive drugs: The relation between structure and potency. J Pharm Pharmacol 1969;21:751.
49. Tuomisto J: A new modification for studying 5-HT uptake by blood platelets: A reevaluation of tricyclic antidepressants as uptake inhibitors. J Pharm Pharmacol 1974;26: 92–100.
50. Lingjaerde O: Inhibitory effect of clomipramine and related drugs on serotonin uptake in platelets: More complicated than previously thought. Psychopharmacology 1979;61: 245–249.
51. Wielosz M, Salmonoa M, Gaetano G, et al: Uptake of 14C-5-hydroxytryptamine by human and rat platelets and its pharmacological inhibition. Naunyn Schmiedbergs Arch Pharmacol 1976;296: 59–65.
52. Le Fur G, Uzan A: Effects of 4-(3-indolyl-alkyl)piperidine derivatives on uptake and release of noradrenaline, dopamine and 5-hydroxytryptamine in rat brain synaptosomes, rat heart and human blood platelets. Biochem Pharmacol 1977;26: 497–503.
53. Briley MS, Langer SZ, Raisman R, et al: 3H-Imipramine binding sites are decreased in platelets of depressed patients. Science 1980;209: 303–305.
54. Paul SM, Rehavi M, Skolnick P, et al: Demonstration of specific ‘high affinity’ binding sites for 3H-imipramine on human platelets. Life Sci 1980;26: 953–959.
55. Briley MS, Raisman R, Langer SZ: Human platelets possess high affinity binding sites for 3H-imipramine. Eur J Pharmacol 1979;58: 347–348.
56. Carroll BJ, Feinberg M, Greden JF, et al: A specific laboratory test for the diagnosis of melancholia: Standardization, validation, and clinical utility. Arch Gen Psychiatry 1981;38: 15–22.